Navigation Links
Avalon Pharmaceuticals names lead development candidate in beta-catenin inhibitor program
Date:6/26/2008

Germantown, MD, June 26, 2008 -- Avalon Pharmaceuticals, Inc. (Nasdaq: AVRX), announced today the nomination of AVN316 as a lead clinical development candidate in its Beta-catenin Pathway Inhibitor program. This novel compound inhibits the Beta-catenin pathway and is a potent inducer of cancer cell death. The Company plans to begin clinical testing of AVN316 in patients in 2009.

Beta-catenin is one of the most commonly activated cancer pathways and is known to play a key role in the initiation and progression of cancer. The Beta-catenin pathway is upregulated in a large number of different cancer types, in particular colon cancer, where it has been estimated to be abnormally activated in at least 90 percent of cases.

"The biological complexity and the classically intractable nature of the beta-catenin protein have prevented this pathway from being effectively targeted by conventional drug discovery techniques, despite the efforts of numerous pharmaceutical companies," stated Kenneth Carter, Ph.D., President and CEO of Avalon Pharmaceuticals, Inc. "We are very pleased to name AVN316 as the lead compound for this intractable target, which we believe provides validation for our unique drug discovery platform, AvalonRx."

Using AvalonRx, the Company identified several chemical compounds series that inhibit beta-catenin function. One family of structurally distinct chemical compounds potently down-regulate the Beta-catenin pathway by reducing beta-catenin protein levels. This lead compound series (of which AVN316 is a member) decreases the beta-catenin protein levels in cancer cells and xenograft tumors, induces biomarkers of Beta-catenin pathway inhibition, and inhibits tumor growth. AVN316 was chosen from the series for its potency and tumor growth inhibition properties in animal models of human disease. Near-term activities with AVN316 include toxicology studies and large-scale manufacturing in preparation for IND submission to the FDA.


'/>"/>

Contact: Kate Gormley
kgormley@dorland.com
215-928-2720
Dorland Global Public Relations
Source:Eurekalert

Related medicine news :

1. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
2. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
3. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
4. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
5. Vista Partners Updates Coverage on Tapestry Pharmaceuticals
6. Transcept Pharmaceuticals, Inc. to Present at UBS 2007 Global Life Sciences Conference
7. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on Tapestry Pharmaceuticals, Inc.
8. Amylin Pharmaceuticals to Webcast Corporate Overview During 43rd Annual Meeting of the European Association for the Study of Diabetes
9. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
10. Provectus Pharmaceuticals, Inc. releases summary results of phase 1 metastatic melanoma study
11. Class Settlement Could Result in Considerable Savings for Certain Consumers of Prescription Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... Wethersfield, Conn. (PRWEB) , ... March 28, 2017 ... ... company based in Wethersfield, Conn., has relocated its corporate headquarters to a new, ... and clients. , In October 2016, Qualidigm purchased a distressed office building ...
(Date:3/28/2017)... ... March 28, 2017 , ... With less than 10,000 dermatologists in the ... care can be limited while the desire to conquer breakouts and eliminate skincare stress ... for every customer online, today released its inaugural survey on the State of Acne ...
(Date:3/28/2017)... ... March 28, 2017 , ... In ... Self-Funding Success website has recently developed and published an informational resource that addresses ... created based on common inquiries the site’s team of third party administrator (TPA) ...
(Date:3/28/2017)... Ohio (PRWEB) , ... March 28, 2017 , ... Columbus ... was selected as one of few medical professionals in the country to sit on ... Founder of Juvly Aesthetics, in just 2 years Dr. Harper helped propel the clinic ...
(Date:3/28/2017)... , ... March 28, 2017 , ... ... be offered by the American Association of Integrative Medicine and available for application ... providers at the AutismOne 2017 Conference in Colorado Springs. , Ed Arranga, president ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... 2017 The National University of Singapore ... analytics company, signed a Memorandum of Understanding (MOU) ... in the region. Under this ... and Technology (BIGHEART) at NUS and Holmusk will ... to healthcare IT and medical device development. These ...
(Date:3/27/2017)... 27, 2017  ImMAGE Biotherapeutics (OTCMKTS: IMMG), an early-stage ... early toxicology and efficacy studies. The company is harnessing ... specific protein, MAGE A, in an effort to find ... After 4 weeks of treatment in transgenic ... little toxicity in a full toxicology report of various ...
(Date:3/27/2017)... Calif. , March 27, 2017  Sanderling ... acquired by Ethicon, a division of Johnson & ... System for the treatment of gastro-esophageal reflux disease ... sphincter augmentation (MSA) technology and the procedure is ... centers. Torax Medical was founded by ...
Breaking Medicine Technology: